Agios Shows Pyrukynd Can Reduce Transfusions In Thalassemia

Having already posted Phase III success in non-transfusion dependent patients, Agios’s Pyrukynd now has shown the ability to reduce transfusions in alpha and beta thalassemia patients.

Red Blood Cells
Agios says Pyrukynd can improve red blood cell health to treat thalassemia • Source: Shutterstock: fusebulb

Agios Pharmaceuticals, Inc. unveiled another set of Phase III data showing efficacy for its pyruvate kinase inhibitor Pyrukynd (mitapivat) in thalassemia patients on 3 June, showing therapeutic benefit for patients with transfusion-dependent alpha or beta thalassemia, which it will file by the end of 2024 to expand its earlier approval in non-transfusion-dependent patients to cover all thalassemia patients.

Key Takeaways
  • Agios reports Phase III data showing that Pyrukynd can reduce transfusion dependence in both alpha and beta thalassemia patients.

The top-line data showing a statistically significant transfusion-reduction response in the 258-patient ENERGIZE-T trial follows Phase III data reported by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from R&D

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.